Early Diagnosis Drives Effective PNH Management

Evaluate high-risk patient populations for PNH.

The Diagnostic Pathway can help you identify patients at high risk for PNH, including those with aplastic anemia, myelodysplastic syndromes, and unexplained thromboses.1

Click on the links below to learn about:

PNH in AA and MDS

PNH in Unexplained Thrombosis

CCS Guidelines


Learn more about how to test and manage PNH.

Flow cytometry — a simple, peripheral blood test — is the gold standard diagnostic test for PNH.

Learn more about flow cytometry.

Looking for a high-sensitivity lab? Click here.

Effectively diagnosing and monitoring PNH requires multiple clinical assessments.1 No one symptom or laboratory value provides a complete diagnostic picture — or a prognostic indicator — of PNH or the course of PNH progression.1,3

Soliris is the first humanized monoclonal antibody to reduce hemolysis and its harmful effects in all PNH patients.

Learn more




IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established. Therefore, treatment with Soliris should not alter anticoagulant management.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, and fatigue.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

References: 1. Parker C, Omine M, Richards S, et al, for the International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699-3709. 2. Sugimori C, Chuhjo T, Feng X, et al. Minor population of blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308-1314. 3. Rosse WF. Paroxysmal nocturnal hemoglobinuria. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:331-342.

This site is intended for US audiences only. © Copyright and Terms of Use 1999 - 2010 Alexion Pharmaceuticals. All rights reserved. Site Map | Privacy Policy | Legal | Glossary
SOLUS03-0155-001